Progress in understanding the molecular pathogenesis of human lung cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1378, Issue 1, 1998, Pages

  Sekido, Yoshitaka ^a   Fong, Kwun M ^a   Minna, John D ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

3p; Anergy; Angioge nesis; Apoptosis; Autocrine; BCL2; Cell cycle; Dominant oncogene; Early detection; Lung cancer; Microsatellite alteration; MYC; p16; Paracrine; Preneoplasia; Prevention; Prognosis; RAS; RB; Recessive oncogene; Signal transduction; Smoking; Telomerase; TP53; Tumor suppressor gene

Indexed keywords

ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; TELOMERASE;

ANGIOGENESIS; APOPTOSIS; CANCER PREVENTION; CELL ONCOGENE; CLONAL ANERGY; EARLY DIAGNOSIS; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; MICROSATELLITE INSTABILITY; NONHUMAN; ONCOGENE MYC; ONCOGENE RAS; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; SMOKING; TUMOR SUPPRESSOR GENE;

EID: 0032547380     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-419X(98)00010-9     Document Type: Article

References (324)

1. J.D. Minna, Neoplasms of the lung, in: Fauci et al. (Eds.), Harrison's Principles of Internal Medicine, 14th edn., McGraw-Hill, 1998, pp. 52-562.
2. Viallet J., Sausville E.A. Involvement of signal transduction pathways in lung cancer biology. J. Cell. Biochem. Suppl. 24:1996;228-236.
3. Fathi Z., Way J.W., Corjay M.H., Viallet J., Sausville E.A., Battey J.F. Bombesin receptor structure and expression in human lung carcinoma cell lines. J. Cell. Biochem. Suppl. 24:1996;237-246.
4. Sethi T., Langdon S., Smyth J., Rozengurt E. Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Cancer Res. 52:1992;2737s-2742s.
5. Cuttitta F., Carney D.N., Mulshine J., Moody T.W., Fedorko J., Fischler A., Minna J.D. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer. Nature. 316:1985;823-826.
6. Halmos G., Schally A.V. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095. Proc. Natl. Acad. Sci. USA. 94:1997;956-960.
7. Kelley M.J., Linnoila R.I., Avis I.L., Georgiadis M.S., Cuttitta F., Mulshine J.L., Johnson B.E. Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. Chest. 112:1997;256-261.
8. Richardson G.E., Johnson B.E. The biology of lung cancer. Semin. Oncol. 20:1993;105-127.
9. Spurzem J.R., Rennard S.I., Romberger D.J. Bombesin-like peptides and airway repair: a recapitulation of lung development? Am. J. Respir. Cell Mol. Biol. 16:1997;209-211.
10. Alroy I., Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett. 410:1997;83-86.
11. Rachwal W.J., Bongiorno P.F., Orringer M.B., Whyte R.I., Ethier S.P., Beer D.G. Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. Br. J. Cancer. 72:1995;56-64.
12. Schneider P.M., Hung M.-C., Chiocca S.M., Manning J., Zhao X., Fang K., Roth J.A. Differential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res. 49:1989;4968-4971.
13. Shi D., He G., Cao S., Pan W., Zhang H.Z., Yu D., Hung M.C. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol. Carcinogen. 5:1992;213-218.
14. neu) in human non-small cell carcinomas of the lung. Cancer Res. 50:1990;421-425.
15. Tateishi M., Ishida T., Mitsudomi T., Kaneko S., Sugimachi K. Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur. J. Cancer. 27:1991;1372-1375.
16. Kern J.A., Slebos R.J.C., Top B., Rodenhuis S., Lager D., Robinson R.A., Weiner D., Schwartz D.A. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J. Clin. Invest. 93:1994;516-520.
17. Pfeiffer P., Clausen P.P., Andersen K., Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br. J. Cancer. 74:1996;86-91.
18. Kern J.A., Torney L., Weiner D., Gazdar A., Shepard H.M., Fendly B. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody. Am. J. Respir. Cell Mol. Biol. 9:1993;448-454.
19. Noguchi M., Murakami M., Bennett W., Lupu R., Hui F. Jr., Harris C.C., Gerwin B.I. Biological consequences of overexpression of a transfected c-erbB-2 gene in immortalized human bronchial epithelial cells. Cancer Res. 53:1993;2035-2043.
20. Yu D., Wang S.-S., Dulski K.M., Tsai C.-M., Nicolson G.L., Hung M.-C. c-erbB-2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res. 54:1994;3260-3266.
21. Tsai C.-M., Chang K.-T., Wu L.-H., Chen J.-Y., Gazdar A.F., Mitsudomi T., Chen M.-H., Perng R.-P. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res. 56:1996;206-209.
22. Tsai C.-M., Yu D., Chang K.-T., Wu L.-H., Perng R.-P., Ibrahim N.K., Hung M.-C. Enhanced chemoresistance by elevation of p185neu levels in HER-2/neu-transfected human lung cancer cells. J. Natl. Cancer Inst. 87:1995;682-684.
23. Tateishi M., Ishida T., Mitsudomi T., Kaneko S., Sugimachi K. Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res. 50:1990;7077-7080.
24. Damstrup L., Rygaard K., Spang-Thomsen M., Poulsen H.S. Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines. Cancer Res. 52:1992;3089-3093.
25. Miettinen P.J., Berger J.E., Meneses J., Phung Y., Pedersen R.A., Werb Z., Derynck R. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature. 376:1995;337-341.
26. Miettinen P.J., Warburton D., Bu D., Zhao J.S., Berger J.E., Minoo P., Koivisto T., Allen L., Dobbs L., Werb Z., Derynck R. Impaired lung branching morphogenesis in the absence of functional EGF receptor. Dev. Biol. 186:1997;224-236.
27. Rusch V., Baselga J., Cordon-Cardo C., Orazem J., Zaman M., Hoda S., McIntosh J., Kurie J., Dmitrovsky E. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53:1993;2379-2385.
28. Sekido Y., Takahashi T., Ueda R., Takahashi M., Suzuki H., Nishida K., Tsukamoto T., Hida T., Shimokata K., Zsebo K.M., Takahashi T. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res. 53:1993;1709-1714.
29. Krystal G.W., Hines S.J., Organ C.P. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res. 56:1996;370-376.
30. Quinn K.A., Treston A.M., Unsworth E.J., Miller M.J., Vos M., Grimley C., Battey J., Mulshine J.L., Cuttitta F. Insulin-like growth factor expression in human cancer cell lines. J. Biol. Chem. 271:1996;11477-11483.
31. Antoniades H.N., Galanopoulos T., Neville-Golden J., O'Hara C.J. Malignant epithelial cells in primary human lung carcinomas coexpress in vivo platelet-derived growth factor (PDGF) and PDGF receptor mRNAs and their protein products. Proc. Natl. Acad. Sci. USA. 89:1992;3942-3946.
32. Yanagita K., Matsumoto K., Sekiguchi K., Ishibashi H., Niho Y., Nakamura T. Hepatocyte growth factor may act as a pulmotrophic factor on lung regeneration after acute lung injury. J. Biol. Chem. 268:1993;21212-21217.
33. Rygaard K., Nakamura T., Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts. Br. J. Cancer. 67:1993;37-46.
34. Harvey P., Warn A., Newman P., Perry L.J., Ball R.Y., Warn R.M. Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas. J. Pathol. 180:1996;389-394.
35. Olivero M., Rizzo M., Madeddu R., Casadio C., Pennacchietti S., Nicotra M.R., Prat M., Maggi G., Arena N., Natali P.G., Comoglio P.M., Di Renzo M.F. Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br. J. Cancer. 74:1996;1862-1868.
36. Siegfried J.M., Weissfeld L.A., Singh-Kaw P., Weyant R.J., Testa J.R., Landreneau R.J. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res. 57:1997;433-439.
37. Schmidt L., Duh F.-M., Chen F., Kishida T., Glenn G., Choyke P., Scherer S.W., Zhuang Z., Lubensky I., Dean M., Allikmets R., Chidambaram A., Bergerheim U.R., Feltis J.T., Casadevall C., Zamarron A., Bernues M., Richard S., Lips C.J., Walther M.M., Tsui L.-C., Geil L., Orcutt M.L., Stackhouse T., Lipan J., Slife L., Brauch H., Decker J., Niehans G., Hughson M.D., Moch H., Storkel S., Lerman M.I., Linehan W.M., Zbar B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16:1997;68-73.
38. Maneckjee R., Minna J.D. Opioid and nicotine receptors affect growth regulation of human lung cancer cell lines. Proc. Natl. Acad. Sci. USA. 87:1990;3294-3298.
39. Maneckjee R., Minna J.D. Opioids induce while nicotine suppresses apoptosis in human lung cancer cells. Cell Growth Differ. 5:1994;1033-1040.
40. Wittinghofer A., Scheffzek K., Ahmadian M.R. The interaction of Ras with GTPase-activating proteins. FEBS Lett. 410:1997;63-67.
41. Cooper C.A., Carey F.A., Bubb V.J., Lamb D., Kerr K.M., Wyllie A.H. The pattern of K-ras mutation in pulmonary adenocarcinoma defines a new pathway of tumour development in the human lung. J. Pathol. 181:1997;401-404.
42. Tsuchiya E., Furuta R., Wada N., Nakagawa K., Ishikawa Y., Kawabuchi B., Nakamura Y., Sugano H. High K-ras mutation rates in goblet-cell-type adenocarcinomas of the lungs. J. Cancer Res. Clin. Oncol. 121:1995;577-581.
43. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
44. Slebos R.J., Hruban R.H., Dalesio O., Mooi W.J., Offerhaus G.J., Rodenhuis S. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J. Natl. Cancer Inst. 83:1991;1024-1027.
45. Slebos R.J., Kibbelaar R.E., Dalesio O., Kooistra A., Stam J., Meijer C.J.L.M., Wagenaar S.S., Vanderschueren R.G.J.R.A., van Zandwijk N., Mooi W.J., Bos J.L., Rodenhuis S. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. New Engl. J. Med. 323:1990;561-565.
46. Mitsudomi T., Steinberg S.M., Oie H.K., Mulshine J.L., Phelps R., Viallet J., Pass H., Minna J.D., Gazdar A.F. ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 51:1991;4999-5002.
47. Sugio K., Ishida T., Yokoyama H., Inoue T., Sugimachi K., Sasazuki T. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res. 52:1992;2903-2906.
48. Slebos R.J., Rodenhuis S. The ras gene family in human non-small-cell lung cancer. Monogr. Natl. Cancer Inst. 13:1992;23-29.
49. Rosell R., Li S., Skacel Z., Mate J.L., Maestre J., Canela M., Tolosa E., Armengol P., Barnadas A., Ariza A. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene. 8:1993;2407-2412.
50. Tsai C.-M., Chang K.-T., Perng R.-P., Mitsudomi T., Chen M.-H., Kadoyama C., Gazdar A.F. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J. Natl. Cancer Inst. 85:1993;897-901.
51. Rodenhuis S., Boerrigter L., Top B., Slebos R.J., Mooi W.J., van't Veer L., van Zandwijk N. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J. Clin. Oncol. 15:1997;285-291.
52. Miwa W., Yasuda J., Yashima K., Makino R., Sekiya T. Absence of activating mutations of the RAF1 protooncogene in human lung cancer. Biol. Chem. Hoppe-Seyler. 375:1994;705-709.
53. Bansal A., Ramirez R.D., Minna J.D. Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines. Oncogene. 14:1997;1231-1234.
54. Teng D.H.-F., Perry W.L., Hogan J.K., Baumgard M., Bell R., Berry S., Davis T., Frank D., Frye C., Hattier T., Hu R., Jammulapati S., Janecki T., Leavitt A., Mitchell J.T., Pero R., Sexton D., Schroeder M., Su P.-H., Swedlund B., Kyriakis J.M., Avruch J., Bartel P., Wong A.K.C., Oliphant A., Thomas A., Skolnick M.H., Tavtigian S.V. Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor. Cancer Res. 57:1997;4177-4182.
55. Grandori C., Eisenman R.N. Myc target genes. Trends Biochem. Sci. 22:1997;177-181.
56. Krystal G., Birrer M., Way J., Nau M., Sausville E., Thompson C., Minna J., Battey J. Multiple mechanisms for transcriptional regulation of the myc gene family in small-cell lung cancer. Mol. Cell. Biol. 8:1988;3373-3381.
57. Johnson B.E., Russell E., Simmons A.M., Phelps R., Steinberg S.M., Ihde D.C., Gazdar A.F. MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. J. Cell. Biochem. Suppl. 24:1996;210-217.
58. Sekido Y., Takahashi T., Mäkelä T.P., Obata Y., Ueda R., Hida T., Hibi K., Shimokata K., Alitalo K., Takahashi T. Complex intrachromosomal rearrangement in the process of amplification of the L-myc gene in small-cell lung cancer. Mol. Cell. Biol. 12:1992;1747-1754.
59. Mäkelä T.P., Hellsten E., Vesa J., Hirvonen H., Palotie A., Peltonen L., Alitalo K. The rearranged L-myc fusion gene (RLF) encodes a Zn-15 related zinc finger protein. Oncogene. 11:1995;2699-2704.
60. Ou X., Campau S., Slusher R., Jasti R.K., Mabry M., Kalemkerian G.P. Mechanism of all-trans-retinoic acid-mediated L-myc gene regulation in small cell lung cancer. Oncogene. 13:1996;1893-1899.
61. Fong K.M., Kida Y., Zimmerman P.V., Smith P.J. MYCL genotypes and loss of heterozygosity in non-small-cell lung cancer. Br. J. Cancer. 74:1996;1975-1978.
62. Volm M., Drings P., Wodrich W., van-Kaick G. Expression of oncoproteins in primary human non-small cell lung cancer and incidence of metastases. Clin. Exp. Metastasis. 11:1993;325-329.
63. Wodrich W., Volm M. Overexpression of oncoproteins in non-small cell lung carcinomas of smokers. Carcinogenesis. 14:1993;1121-1124.
64. Szabo E., Riffe M.E., Steinberg S.M., Birrer M.J., Linnoila R.I. Altered cJUN expression: an early event in human lung carcinogenesis. Cancer Res. 56:1996;305-315.
65. Levin W.J., Press M.F., Gaynor R.B., Sukhatme V.P., Boone T.C., Reissmann P.T., Figlin R.A., Holmes E.C., Souza L.M., Slamon D.J. Expression patterns of immediate early transcription factors in human non-small cell lung cancer. Oncogene. 11:1995;1261-1269.
66. Levin N.A., Brzoska P., Gupta N., Minna J.D., Gray J.W., Christman M.F. Identification of frequent novel genetic alterations in small cell lung carcinoma. Cancer Res. 54:1994;5086-5091.
67. Levin N.A., Brzoska P.M., Warnock M.L., Gray J.W., Christman M.F. Identification of novel regions of altered DNA copy number in small cell lung tumors. Genes Chrom. Cancer. 13:1995;175-185.
68. Schwendel A., Langreck H., Reichel M., Schröck E., Ried T., Dietel M., Petersen I. Primary small-cell lung carcinomas and their metastases are characterized by a recurrent pattern of genetic alterations. Int. J. Cancer. 74:1997;86-93.
69. Petersen I., Bujard M., Petersen S., Wolf G., Goeze A., Schwendel A., Langreck H., Gellert K., Reichel M., Just K., du Manoir S., Cremer T., Dietel M., Ried T. Patterns of chromosomal imbalances in adenocarcinoma and squamous cell carcinoma of the lung. Cancer Res. 57:1997;2331-2335.
70. Petersen I., Langreck H., Wolf G., Schwendel A., Psille R., Vogt P., Reichel M.B., Ried T., Dietel M. Small-cell lung cancer is characterized by a high incidence of deletions on chromosomes 3p, 4q, 5q, 10q, 13q and 17p. Br. J. Cancer. 75:1997;79-86.
71. Ohmori T., Podack E.R., Nishio K., Takahashi M., Miyahara Y., Takeda Y., Kubota N., Funayama Y., Ogasawara H., Ohira T., Ohta S., Saijo N. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem. Biophys. Res. Commun. 192:1993;30-36.
72. Ziegler A., Luedke G.H., Fabbro D., Altmann K.H., Stahel R.A., Zangemeister-Wittke U. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J. Natl. Cancer Inst. 89:1997;1027-1036.
73. Jiang S.X., Sato Y., Kuwao S., Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J. Pathol. 177:1995;135-138.
74. Kaiser U., Schilli M., Haag U., Neumann K., Kreipe H., Kogan E., Havemann K. Expression of bcl-2-protein in small cell lung cancer. Lung Cancer. 15:1996;31-40.
75. Jiang S.X., Kameya T., Sato Y., Yanase N., Yoshimura H., Kodama T. Bcl-2 protein expression in lung cancer and close correlation with neuroendocrine differentiation. Am. J. Pathol. 148:1996;837-846.
76. Pezzella F., Turley H., Kuzu I., Tungekar M.F., Dunnill M.S., Pierce C.B., Harris A., Gatter K.C., Mason D.Y. bcl-2 protein in non-small-cell lung carcinoma. New Engl. J. Med. 329:1993;690-694.
77. Higashiyama M., Doi O., Kodama K., Yokouchi H., Nakamori S., Tateishi R. bcl-2 oncoprotein in surgically resected nonsmall cell lung cancer: possibly favorable prognostic factor in association with low incidence of distant metastasis. J. Surg. Oncol. 64:1997;48-54.
78. Apolinario R.M., van der Valk P., de Jong J.S., Deville W., van Ark-Otte J., Dingemans A.M., van Mourik J.C., Postmus P.E., Pinedo H.M., Giaccone G. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J. Clin. Oncol. 15:1997;2456-2466.
79. Fontanini G., Vignati S., Bigini D., Mussi A., Lucchi M., Angeletti C.A., Basolo F., Bevilacqua G. Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer. Br. J. Cancer. 71:1995;1003-1007.
80. Cheng E.H.-Y., Kirsch D.G., Clem R.J., Ravi R., Kastan M.B., Bedi A., Ueno K., Hardwick J.M. Conversion of Bcl-2 to a Bax-like death effector by caspases. Science. 278:1997;1966-1968.
81. Kitagawa Y., Wong F., Lo P., Elliott M., Verburgt L.M., Hogg J.C., Daya M. Overexpression of Bcl-2 and mutations in p53 and K-ras in resected human non-small cell lung cancers. Am. J. Respir. Cell Mol. Biol. 15:1996;45-54.
82. Yin C., Knudson C.M., Korsmeyer S.J., Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 385:1997;637-640.
83. Brambilla E., Negoescu A., Gazzeri S., Lantuejoul S., Moro D., Brambilla C., Coll J.L. Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am. J. Pathol. 149:1996;1941-1952.
84. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
85. Angeletti C.A., Lucchi M., Fontanini G., Mussi A., Chella A., Ribechini A., Vignati S., Bevilacqua G. Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (stage IIIA-N2). Impact of adjuvant therapies in a subset of patients at high risk of recurrence. Cancer. 78:1996;409-415.
86. Fontanini G., Lucchi M., Vignati S., Mussi A., Ciardiello F., De Laurentiis M., De Placido S., Basolo F., Angeletti C.A., Bevilacqua G. Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. J. Natl. Cancer Inst. 89:1997;881-886.
87. Pastorino U., Andreola S., Tagliabue E., Pezzella F., Incarbone M., Sozzi G., Buyse M., Menard S., Pierotti M., Rilke F. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J. Clin. Oncol. 15:1997;2858-2865.
88. Pezzella F., Pastorino U., Tagliabue E., Andreola S., Sozzi G., Gasparini G., Menard S., Gatter K.C., Harris A.L., Fox S., Buyse M., Pilotti S., Pierotti M., Rilke F. Non-small-cell carcinoma tumor growth without morphological evidence of neo-angiogenesis. Am. J. Pathol. 151:1997;1417-1423.
89. Mattern J., Koomägi R., Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br. J. Cancer. 73:1996;931-934.
90. Fontanini G., Vignati S., Lucchi M., Mussi A., Calcinai A., Boldrini L., Chine S., Silvestri V., Angeletti C.A., Basolo F., Bevilacqua G. Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression. Br. J. Cancer. 75:1997;1295-1301.
91. Volm M., Koomägi R., Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int. J. Cancer. 74:1997;64-68.
92. Ohta Y., Watanabe Y., Murakami S., Oda M., Hayashi Y., Nonomura A., Endo Y., Sasaki T. Vascular endothelial growth factor and lymph node metastasis in primary lung cancer. Br. J. Cancer. 76:1997;1041-1045.
93. Takanami I., Imamura T., Hashizume T., Kikuchi K., Yamamoto Y., Yamamoto T., Kodaira S. Immunohistochemical detection of basic fibroblast growth factor as a prognostic indicator in pulmonary adenocarcinoma. Jpn. J. Clin. Oncol. 26:1996;293-297.
94. Volm M., Koomägi R., Mattern J., Stammler G. Prognostic value of basic fibroblast growth factor and its receptor (FGFR-1) in patients with non-small cell lung carcinomas. Eur. J. Cancer. 33:1997;691-693.
95. Koukourakis M.I., Giatromanolaki A., O'Byrne K.J., Comley M., Whitehouse R.M., Talbot D.C., Gatter K.C., Harris A.L. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. Br. J. Cancer. 75:1997;477-481.
96. Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 265:1994;1582-1584.
97. Arenberg D.A., Kunkel S.L., Polverini P.J., Morris S.B., Burdick M.D., Glass M.C., Taub D.T., Iannettoni M.D., Whyte R.I., Strieter R.M. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184:1996;981-992.
98. Boehm T., Folkman J., Browder T., O'Reilly M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 390:1997;404-407.
99. Arenberg D.A., Kunkel S.L., Polverini P.J., Glass M., Burdick M.D., Strieter R.M. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest. 97:1996;2792-2802.
100. Whang-Peng J., Kao-Shan C.S., Lee E.C., Bunn P.A., Carney D.N., Gazdar A.F., Minna J.D. Specific chromosome defect associated with human small-cell lung cancer: deletion 3p(14-23). Science. 215:1982;181-182.
101. A.K. Virmani, K.M. Fong, D. Kodagoda, D. McIntire, J. Hung, V. Tonk, J.D. Minna, A.F. Gazdar, Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types, Gene Chrom. Cancer, in press.
102. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
103. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., Giaccia A.J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 379:1996;88-91.
104. Hainaut P., Soussi T., Shomer B., Hollstein M., Greenblatt M., Hovig E., Harris C.C., Montesano R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res. 25:1997;151-157.
105. Casey G., Lopez M.E., Ramos J.C., Plummer S.J., Arboleda M.J., Shaughnessy M., Karlan B., Slamon D.J. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene. 13:1996;1971-1981.
106. Eerola A.-K., Törmänen U., Rainio P., Sormunen R., Bloigu R., Vähäkangas K., Lehto V.-P., Soini Y., Pääkkö P. Apoptosis in operated small cell lung carcinoma is inversely related to tumour necrosis and p53 immunoreactivity. J. Pathol. 181:1997;172-177.
107. Nishio M., Koshikawa T., Kuroishi T., Suyama M., Uchida K., Takagi Y., Washimi O., Sugiura T., Ariyoshi Y., Takahashi T., Ueda R., Takahashi T. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J. Clin. Oncol. 14:1996;497-502.
108. Konishi T., Lin Z., Fujino S., Kato H., Mori A. Association of p53 protein expression in stage I lung adenocarcinoma with reference to cytological subtypes. Hum. Pathol. 28:1997;544-548.
109. Ishida H., Irie K., Itoh T., Furukawa T., Tokunaga O. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer. 80:1997;1034-1045.
110. Lavigueur A., Maltby V., Mock D., Rossant J., Pawson T., Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol. 9:1989;3982-3991.
111. Takahashi T., Carbone D., Takahashi T., Nau M.M., Hida T., Linnoila I., Ueda R., Minna J.D. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res. 52:1992;2340-2343.
112. Adachi J., Ookawa K., Shiseki M., Okazaki T., Tsuchida S., Morishita K., Yokota J. Induction of apoptosis but not G1 arrest by expression of the wild-type p53 gene in small cell lung carcinoma. Cell Growth Differ. 7:1996;879-886.
113. Roth J.A., Nguyen D., Lawrence D.D., Kemp B.L., Carrasco C.H., Ferson D.Z., Hong W.K., Komaki R., Lee J.J., Nesbitt J.C., Pisters K.M., Putnam J.B., Schea R., Shin D.M., Walsh G.L., Dolormente M.M., Han C.I., Martin F.D., Yen N., Xu K., Stephens L.C., McDonnell T.J., Mukhopadhyay T., Cai D. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med. 2:1996;985-991.
114. Denissenko M.F., Pao A., Tang M., Pfeifer G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science. 274:1996;430-432.
115. Graziano S.L. Non-small cell lung cancer: clinical value of new biological predictors. Lung Cancer. 17:1997;S37-58.
116. Schlichtholz B., Trédaniel J., Lubin R., Zalcman G., Hirsch A., Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br. J. Cancer. 69:1994;809-816.
117. Winter S.F., Minna J.D., Johnson B.E., Takahashi T., Gazdar A.F., Carbone D.P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 52:1992;4168-4174.
118. Lubin R., Zalcman G., Bouchet L., Tredanel J., Legros Y., Cazals D., Hirsch A., Soussi T. Serum p53 antibodies as early markers of lung cancer. Nature Med. 1:1995;701-702.
119. Rosenfeld M.R., Malats N., Schramm L., Graus F., Cardenal F., Vinolas N., Rosell R., Tora M., Real F.X., Posner J.B., Dalmau J. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J. Natl. Cancer Inst. 89:1997;381-385.
120. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.-C., Valent A., Minty A., Chalon P., Lelias J.-M., Dumont X., Ferrara P., McKeon F., Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90:1997;809-819.
121. Jost C.A., Marin M.C., Kaelin W.G.J. p73 is a human p53-related protein that can induce apoptosis. Nature. 389:1997;191-194.
122. Shimizu T., Miwa W., Nakamori S., Ishikawa O., Konishi Y., Sekiya T. Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers. Jpn. J. Cancer Res. 87:1996;275-278.
123. Marchetti A., Doglioni C., Barbareschi M., Buttitta F., Pellegrini S., Bertacca G., Chella A., Merlo G., Angeletti C.A., Dalla Palma P., Bevilacqua G. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene. 12:1996;1319-1324.
124. Shieh S.-Y., Ikeda M., Taya Y., Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91:1997;325-334.
125. Higashiyama M., Doi O., Kodama K., Yokouchi H., Kasugai T., Ishiguro S., Takami K., Nakayama T., Nishisho I. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation. Br. J. Cancer. 75:1997;1302-1308.
126. Peeper D.S., Upton T.M., Ladha M.H., Neuman E., Zalvide J., Bernards R., DeCaprio J.A., Ewen M.E. Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature. 386:1997;177-181.
127. White R.J., Trouche D., Martin K., Jackson S.P., Kouzarides T. Repression of RNA polymerase III transcription by the retinoblastoma protein. Nature. 382:1996;88-90.
128. Yamasaki L., Jacks T., Bronson R., Goillot E., Harlow E., Dyson N.J. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell. 85:1996;537-548.
129. Harbour J.W., Lai S.L., Whang-Peng J., Gazdar A.F., Minna J.D., Kaye F.J. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 241:1988;353-357.
130. Horowitz J.M., Park S.H., Bogenmann E., Cheng J.C., Yandell D.W., Kaye F.J., Minna J.D., Dryja T.P., Weinberg R.A. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc. Natl Acad. Sci. USA. 87:1990;2775-2779.
131. Reissmann P.T., Koga H., Takahashi R., Figlin R.A., Holmes E.C., Piantadosi S., Cordon-Cardo C., Slamon D.J. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. Oncogene. 8:1993;1913-1919.
132. Cagle P.T., El-Naggar A.K., Xu H.-J., Hu S.-X., Benedict W.F. Differential retinoblastoma protein expression in neuroendocrine tumors of the lung. Potential diagnostic implications. Am. J. Pathol. 150:1997;393-400.
133. Dosaka-Akita H., Hu S.-X., Fujino M., Harada M., Kinoshita I., Xu H.-J., Kuzumaki N., Kawakami Y., Benedict W.F. Altered retinoblastoma protein expression in nonsmall cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Cancer. 79:1997;1329-1337.
134. Mori N., Yokota J., Akiyama T., Sameshima Y., Okamoto A., Mizoguchi H., Toyoshima K., Sugimura T., Terada M. Variable mutations of the RB gene in small-cell lung carcinoma. Oncogene. 5:1990;1713-1717.
135. Kaye F.J., Kratzke R.A., Gerster J.L., Horowitz J.M. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA. 87:1990;6922-6926.
136. Sanders B.M., Jay M., Draper G.J., Roberts E.M. Non-ocular cancer in relatives of retinoblastoma patients. Br. J. Cancer. 60:1989;358-365.
137. Ookawa K., Shiseki M., Takahashi R., Yoshida Y., Terada M., Yokota J. Reconstitution of the RB gene suppresses the growth of small-cell lung carcinoma cells carrying multiple genetic alterations. Oncogene. 8:1993;2175-2181.
138. Xu H.-J., Quinlan D.C., Davidson A.G., Hu S.-X., Summers C.L., Li J., Benedict W.F. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J. Natl. Cancer Inst. 86:1994;695-699.
139. Shimizu E., Coxon A., Otterson G.A., Steinberg S.M., Kratzke R.A., Kim Y.W., Fedorko J., Oie H., Johnson B.E., Mulshine J.L., Minna J.D., Gazdar A.F., Kaye F.J. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene. 9:1994;2441-2448.
140. INK4a expression in resected non-small cell lung tumors. Cancer Res. 56:1996;3415-3420.
141. Tamura K., Zhang X., Murakami Y., Hirohashi S., Xu H.J., Hu S.X., Benedict W.F., Sekiya T. Deletion of three distinct regions on chromosome 13q in human non-small-cell lung cancer. Int. J. Cancer. 74:1997;45-49.
142. Baldi A., Esposito V., de Luca A., Howard C.M., Mazzarella G., Baldi F., Caputi M., Giordano A. Differential expression of the retinoblastoma gene family members pRb/p105, p107, and pRb2/p130 in lung cancer. Clin. Cancer Res. 2:1996;1239-1245.
143. Helin K., Holm K., Niebuhr A., Eiberg H., Tommerup N., Hougaard S., Poulsen H.S., Spang-Thomsen M., Nørgaard P. Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc. Natl. Acad. Sci. USA. 94:1997;6933-6938.
144. Schauer I.E., Siriwardana S., Langan T.A., Sclafani R.A. Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc. Natl. Acad. Sci. USA. 91:1994;7827-7831.
145. Betticher D.C., Heighway J., Hasleton P.S., Altermatt H.J., Ryder W.D., Cerny T., Thatcher N. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br. J. Cancer. 73:1996;294-300.
146. Reifenberger G., Ichimura K., Reifenberger J., Elkahloun A.G., Meltzer P.S., Collins V.P. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets. Cancer Res. 56:1996;5141-5145.
147. Merlo A., Gabrielson E., Askin F., Sidransky D. Frequent loss of chromosome 9 in human primary non-small cell lung cancer. Cancer Res. 54:1994;640-642.
148. Kishimoto Y., Sugio K., Mitsudomi T., Oyama T., Virmani A.K., McIntire D.D., Gazdar A.F. Frequent loss of the short arm of chromosome 9 in resected
149. Neville E.M., Stewart M., Myskow M., Donnelly R.J., Field J.K. Loss of heterozygosity at 9p23 defines a novel locus in non-small cell lung cancer. Oncogene. 11:1995;581-585.
150. Kim S.K., Ro J.Y., Kemp B.L., Lee J.S., Kwon T.J., Fong K.M., Sekido Y., Minna J.D., Hong W.K., Mao L. Identification of three distinct tumor suppressor loci on the short arm of chromosome 9 in small cell lung cancer. Cancer Res. 57:1997;400-403.
151. Pollock P.M., Pearson J.V., Hayward N.K. Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chrom. Cancer. 15:1996;77-88.
152. Hayashi N., Sugimoto Y., Tsuchiya E., Ogawa M., Nakamura Y. Somatic mutations of the MTS (multiple tumor suppressor) 1/CDK4l (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem. Biophys. Res. Commun. 202:1994;1426-1430.
153. de Vos S., Miller C.W., Takeuchi S., Gombart A.F., Cho S.K., Koeffler H.P. Alterations of CDKN2 (p16) in non-small cell lung cancer. Genes Chrom. Cancer. 14:1995;164-170.
154. Xiao S., Li D., Corson J.M., Vijg J., Fletcher J.A. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res. 55:1995;2968-2971.
155. Washimi O., Nagatake M., Osada H., Ueda R., Koshikawa T., Seki T., Takahashi T., Takahashi T. In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res. 55:1995;514-517.
156. Shimizu T., Sekiya T. Loss of heterozygosity at 9p21 loci and mutations of the MTS1 and MTS2 genes in human lung cancers. Int. J. Cancer. 63:1995;616-620.
157. INK4B and p18 genes in primary non-small-cell lung cancers. Int. J. Cancer. 65:1996;734-739.
158. Takeshima Y., Nishisaka T., Kawano R., Kishizuchi K., Fujii S., Kitaguchi S., Inai K. p16/CDKN2 gene and p53 gene alterations in Japanese non-smoking female lung adenocarcinoma. Jpn. J. Cancer Res. 87:1996;134-140.
159. Marchetti A., Buttitta F., Pellegrini S., Bertacca G., Chella A., Carnicelli V., Tognoni V., Filardo A., Angeletti C.A., Bevilacqua G. Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. J. Pathol. 181:1997;178-182.
160. Wiest J.S., Franklin W.A., Otstot J.T., Forbey K., Varella-Garcia M., Rao K., Drabkin H., Gemmill R., Ahrent S., Sidransky D., Saccomanno G., Fountain J.W., Anderson M.W. Identification of a novel region of homozygous deletion on chromosome 9p in squamous cell carcinoma of the lung: the location of a putative tumor suppressor gene. Cancer Res. 57:1997;1-6.
161. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., Baylin S.B., Sidransky D. 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med. 1:1995;686-692.
162. INK4 protein induction by 5-aza 2′deoxycytidine. Oncogene. 11:1995;1211-1216.
163. INK4A inactivation in non-small cell lung cancer cell lines. Cancer Res. 55:1995;6200-6209.
164. INK4 in human cancer. Proc. Natl. Acad. Sci. USA. 91:1994;11045-11049.
165. INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene. 9:1994;3375-3378.
166. Nakagawa K., Conrad N.K., Williams J.P., Johnson B.E., Kelley M.J. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. Oncogene. 11:1995;1843-1851.
167. Kelley M.J., Nakagawa K., Steinberg S.M., Mulshine J.L., Kamb A., Johnson B.E. Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J. Natl. Cancer Inst. 87:1995;756-761.
168. Sakaguchi M., Fujii Y., Hirabayashi H., Yoon H.E., Komoto Y., Oue T., Kusafuka T., Okada A., Matsuda H. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study. Int. J. Cancer. 65:1996;442-445.
169. INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res. 56:1996;5557-5562.
170. INK4 expression in primary lung cancers and cell lines. Cancer Res. 55:1995;505-509.
171. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 55:1995;1448-1451.
172. INK4 expression in nonsmall cell lung carcinoma. Cancer. 80:1997;389-395.
173. Quelle D.E., Zindy F., Ashmun R.A., Sherr C.J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83:1995;993-1000.
174. ARF. Cell. 91:1997;649-659.
175. INK4D cyclin dependent kinase inhibitor gene is altered in osteosarcoma. Oncogene. 15:1997;231-235.
176. Kawamata N., Morosetti R., Miller C.W., Park D., Spirin K.S., Nakamaki T., Takeuchi S., Hatta Y., Simpson J., Wilcyznski S., Lee Y.Y., Bartram C.R., Koeffler H.P. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 55:1995;2266-2269.
177. Esposito V., Baldi A., De Luca A., Groger A.M., Loda M., Giordano G.G., Caputi M., Baldi F., Pagano M., Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 57:1997;3381-3385.
178. KIP2 gene at 11p15.5. Oncogene. 12:1996;1365-1368.
179. Naylor S.L., Johnson B.E., Minna J.D., Sakaguchi A.Y. Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature. 329:1987;451-454.
180. Kok K., Osinga J., Carritt B., Davis M.B., van der Hout A.H., van der Veen A.Y., Landsvater R.M., de Leij L.F.M.H., Berendsen H.H., Postmus P.E., Poppema S., Buys C.H.C.M. Deletion of a DNA sequence at the chromosomal region 3p21 in all major types of lung cancer. Nature. 330:1987;578-581.
181. Hibi K., Takahashi T., Yamakawa K., Ueda R., Sekido Y., Ariyoshi Y., Suyama M., Takagi H., Nakamura Y., Takahashi T. Three distinct regions involved in 3p deletion in human lung cancer. Oncogene. 7:1992;445-449.
182. Rabbitts P., Bergh J., Douglas J., Collins F., Waters J. A submicroscopic homozygous deletion at the D3S3 locus in a cell line isolated from a small cell lung carcinoma. Genes Chromosomes Cancer. 2:1990;231-238.
183. Drabkin H.A., Mendez M.J., Rabbitts P.H., Varkony T., Bergh J., Schlessinger J., Erickson P., Gemmill R.M. Characterization of the submicroscopic deletion in the small-cell lung carcinoma (SCLC) cell line U2020. Genes Chrom. Cancer. 5:1992;67-74.
184. Latif F., Tory K., Modi W.S., Graziano S.L., Gamble G., Douglas J., Heppell-Parton A.C., Rabbitts P.H., Zbar B., Lerman M.I. Molecular characterization of a large homozygous deletion in the small cell lung cancer cell line U2020: a strategy for cloning the putative tumor suppressor gene. Genes Chrom. Cancer. 5:1992;119-127.
185. Todd S., Franklin W.A., Varella-Garcia M., Kennedy T., Hilliker C. Jr., Hahner L., Anderson M., Wiest J.S., Drabkin H.A., Gemmill R.M. Homozygous deletions of human chromosome 3p in lung tumors. Cancer Res. 57:1997;1344-1352.
186. Daly M.C., Xiang R.-H., Buchhagen D., Hensel C.H., Garcia D.K., Killary A.M., Minna J.D., Naylor S.L. A homozygous deletion on chromosome 3 in a small cell lung cancer cell line correlates with a region of tumor suppressor activity. Oncogene. 8:1993;1721-1729.
187. Kok K., van den Berg A., Veldhuis P.M.J.F., van der Veen A.Y., Franke M., Schoenmakers E.F.P.M., Hulsbeek M.M.F., van der Hout A.H., de Leij L., van de Ven W., Buys C.H.C.M. A homozygous deletion in a small cell lung cancer cell line involving a 3p21 region with a marked instability in yeast artificial chromosomes. Cancer Res. 54:1994;4183-4187.
188. Roche J., Boldog F., Robinson M., Robinson L., Varella-Garcia M., Swanton M., Waggoner B., Fishel R., Franklin W., Gemmill R., Drabkin H. Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene. 12:1996;1289-1297.
189. Wei M.-H., Latif F., Bader S., Kashuba V., Chen J.-Y., Duh F.-M., Sekido Y., Lee C.-C., Geil L., Kuzmin I., Zabarovsky E., Klein G., Zbar B., Minna J.D., Lerman M.I. Construction of a 600-kilobase cosmid clone contig and generation of a transcriptional map surrounding the lung cancer tumor suppressor gene (TSG) locus on human chromosome 3p21.3: progress toward the isolation of a lung cancer TSG. Cancer Res. 56:1996;1487-1492.
190. Sithanandam G., Latif F., Duh F.-M., Bernal R., Smola U., Li H., Kuzmin I., Wixler V., Geil L., Shrestha S., Lloyd P.A., Bader S., Sekido Y., Tartof K.D., Kashuba V.I., Zabarovsky E.R., Dean M., Klein G., Lerman M.I., Minna J.D., Rapp U.R., Allikmets R. 3pK, a new mitogen-activated protein kinase-activated protein kinase located in the small cell lung cancer tumor suppressor gene region. Mol. Cell. Biol. 16:1996;868-876.
191. Sekido Y., Bader S., Latif F., Chen J.-Y., Duh F.-M., Wei M.-H., Albanesi J.P., Lee C.-C., Lerman M.I., Minna J.D. Human semaphorins A(V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns. Proc. Natl. Acad. Sci. USA. 93:1996;4120-4125.
192. Xiang R.H., Hensel C.H., Garcia D.K., Carlson H.C., Kok K., Daly M.C., Kerbacher K., van den Berg A., Veldhuis P., Buys C.H.C.M., Naylor S.L. Isolation of the human semaphorin III/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer. Genomics. 32:1996;39-48.
193. Latif F., Duh F.-M., Bader S., Sekido Y., Li H., Geil L., Zbar B., Minna J.D., Lerman M.I. The human homolog of the rodent immediate early response genes, PC4 and TIS7, resides in the lung cancer tumor suppressor gene region on chromosome 3p21. Hum. Genet. 99:1997;334-341.
194. Y. Sekido, M. Ahmadian, I. Wistuba, F. Latif, S. Bader, M.-H. Wei, F.-M. Duh, A. Gazdar, M. Lerman, J. Minna, Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene, Oncogene 15, in press.
195. Yamakawa K., Takahashi T., Horio Y., Murata Y., Takahashi E., Hibi K., Yokoyama S., Ueda R., Takahashi T., Nakamura Y. Frequent homozygous deletions in lung cancer cell lines detected by a DNA marker located at 3p21.3-p22. Oncogene. 8:1993;327-330.
196. Hibi K., Yamakawa K., Ueda R., Horio Y., Murata Y., Tamari M., Uchida K., Takahashi T., Nakamura Y., Takahashi T. Aberrant upregulation of a novel integrin alpha subunit gene at 3p21.3 in small cell lung cancer. Oncogene. 9:1994;611-619.
197. Ishikawa S., Kai M., Tamari M., Takei Y., Takeuchi K., Bandou H., Yamane Y., Ogawa M., Nakamura Y. Sequence analysis of a 685-kb genomic region on chromosome 3p22-p21.3 that is homozygously deleted in a lung carcinoma cell line. DNA Res. 4:1997;35-43.
198. X. Wu, Y. Zhao, S.E. Honn, G.E. Tomlinson, J.D. Minna, W.K. Hong, M.R. Spitz, Benzo[a]pyrene diol expoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer, Cancer Res. 58, in press.
199. Sozzi G., Veronese M.L., Negrini M., Baffa R., Cotticelli M.G., Inoue H., Tornielli S., Pilotti S., De Gregorio L., Pastorino U., Pierotti M.A., Ohta M., Huebner K., Croce C.M. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell. 85:1996;17-26.
200. Fong K.M., Biesterveld E.J., Virmani A., Wistuba I., Sekido Y., Bader S.A., Ahmadian M., Ong S.T., Rassool F.V., Zimmerman P.V., Giaccone G., Gazdar A.F., Minna J.D. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res. 57:1997;2256-2267.
201. Yanagisawa K., Kondo M., Osada H., Uchida K., Takagi K., Masuda A., Takahashi T., Takahashi T. Molecular analysis of the FHIT gene at 3p14.2 in lung cancer cell lines. Cancer Res. 56:1996;5579-5582.
202. Sozzi G., Sard L., De Gregorio L., Marchetti A., Musso K., Buttitta F., Tornielli S., Pellegrini S., Veronese M.L., Manenti G., Incarbone M., Chella A., Angeletti C.A., Pastorino U., Huebner K., Bevilaqua G., Pilotti S., Croce C.M., Pierotti M.A. Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res. 57:1997;2121-2123.
203. Sozzi G., Tornielli S., Tagliabue E., Sard L., Pezzella F., Pastorino U., Minoletti F., Pilotti S., Ratcliffe C., Veronese M.L., Goldstraw P., Huebner K., Croce C.M., Pierotti M.A. Absense of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res. 57:1997;5207-5212.
204. Siprashvili Z., Sozzi G., Barnes L.D., McCune P., Robinson A.K., Eryomin V., Sard L., Tagliabue E., Greco A., Fusetti L., Schwartz G., Pierotti M.A., Croce C.M., Huebner K. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc. Natl. Acad. Sci. USA. 94:1997;13771-13776.
205. Otterson G.A., Xiao G.-H., Geradts J., Jin F., Chen W., Niklinska W., Kaye F.J., Yeung R.S. Protein expression and functional analysis of the FHIT gene in human tumor cells. J Natl. Cancer Inst. 90:1998;426-432.
206. Sekido Y., Bader S., Latif F., Gnarra J.R., Gazdar A.F., Linehan W.M., Zbar B., Lerman M.I., Minna J.D. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene. 9:1994;1599-1604.
207. Papadopoulos N., Nicolaides N.C., Wei Y.-F., Ruben S.M., Carter K.C., Rosen C.A., Haseltine W.A., Fleischmann R.D., Fraser C.M., Adams M.D., Venter J.C., Hamilton S.R., Petersen G.M., Watson P., Lynch H.T., Peltomäki P., Mecklin J.-P., de la Chapelle A., Kinzler K.W., Vogelstein B. Mutation of a mutL homolog in hereditary colon cancer. Science. 263:1994;1625-1629.
208. Jensen D.E., Proctor M., Marquis S.T., Gardner H.P., Ha S.I., Chodosh L.A., Ishov A.M., Tommerup N., Vissing H., Sekido Y., Minna J.D., Borodovsky A., Schultz D.C., Wilkinson K.D., Maul G.G., Barlev N., Berger S.L., Prendergast G.C., Rauscher III F.J. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene. 16:1998;1097-1112.
209. Chytil F. Retinoids in lung development. FASEB J. 10:1996;986-992.
210. Minna J.D., Mangelsdorf D.J. Retinoic acid receptor expression abnormalities in lung cancer: important clues or major obstacles? J. Natl. Cancer. Inst. 89:1997;602-604.
211. Gebert J.F., Moghal N., Frangioni J.V., Sugarbaker D.J., Neel B.G. High frequency of retinoic acid receptor beta abnormalities in human lung cancer. Oncogene. 6:1991;1859-1868.
212. Nervi C., Vollberg T.M., George M.D., Zelent A., Chambon P., Jetten A.M. Expression of nuclear retinoic acid receptors in normal tracheobronchial cells and in lung carcinoma cells. Exp. Cell Res. 195:1991;163-170.
213. Geradts J., Chen J.-Y., Russell E.K., Yankaskas J.R., Nieves L., Minna J.D. Human lung cancer cell lines exhibit resistance to retinoic acid treatment. Cell Growth Differ. 4:1993;799-809.
214. Zhang X.K., Liu Y., Lee M.O., Pfahl M. A specific defect in the retinoic acid response associated with human lung cancer cell lines. Cancer Res. 54:1994;5663-5669.
215. Moghal N., Neel B.G. Evidence for impaired retinoic acid receptor-thyroid hormone receptor AF-2 cofactor activity in human lung cancer. Mol. Cell. Biol. 15:1995;3945-3959.
216. Houle B., Leduc F., Bradley W.E. Implication of RARB in epidermoid (squamous) lung cancer. Genes Chrom. Cancer. 3:1991;358-366.
217. Xu X.C., Sozzi G., Lee J.S., Lee J.J., Pastorino U., Pilotti S., Kurie J.M., Hong W.K., Lotan R. Suppression of retinoic acid receptor β in non-small-cell lung cancer in vivo: implications for lung cancer development. J. Natl. Cancer Inst. 89:1997;624-629.
218. Houle B., Rochette-Egly C., Bradley W.E.C. Tumor-suppressive effect of the retinoic acid receptor β in human epidermoid lung cancer cells. Proc. Natl. Acad. Sci. USA. 90:1993;985-989.
219. Berard J., Laboune F., Mukuna M., Masse S., Kothary R., Bradley W.E. Lung tumors in mice expressing an antisense RARβ2 transgene. FASEB J. 10:1996;1091-1097.
220. Lu X.P., Fanjul A., Picard N., Pfahl M., Rungta D., Nared-Hood K., Carter B., Piedrafita J., Tang S., Fabbrizio E., Pfahl M. Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nat. Med. 3:1997;686-690.
221. Gerwin B.I., Spillare E., Forrester K., Lehman T.A., Kispert J., Welsh J.A., Pfeifer A.M., Lechner J.F., Baker S.J., Vogelstein B., Harris C.C. Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc. Natl. Acad. Sci. USA. 89:1992;2759-2763.
222. Nørgaard P., Spang-Thomsen M., Poulsen H.S. Expression and autoregulation of transforming growth factor β receptor mRNA in small-cell lung cancer cell lines. Br. J. Cancer. 73:1996;1037-1043.
223. Tani M., Takenoshita S., Kohno T., Hagiwara K., Nagamachi Y., Harris C.C., Yokota J. Infrequent mutations of the transforming growth factor beta-type II receptor gene at chromosome 3p22 in human lung cancers with chromosome 3p deletions. Carcinogenesis. 18:1997;1119-1121.
224. Takenoshita S., Hagiwara K., Gemma A., Nagashima M., Ryberg D., Lindstedt B.A., Bennett W.P., Haugen A., Harris C.C. Absence of mutations in the transforming growth factor-β type II receptor in sporadic lung cancers with microsatellite instability and rare H-ras1 alleles. Carcinogenesis. 18:1997;1427-1429.
225. Nagatake M., Takagi Y., Osada H., Uchida K., Mitsudomi T., Saji S., Shimokata K., Takahashi T., Takahashi T. Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. Cancer Res. 56:1996;2718-2720.
226. Uchida K., Nagatake M., Osada H., Yatabe Y., Kondo M., Mitsudomi T., Masuda A., Takahashi T., Takahashi T. Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res. 56:1996;5583-5585.
227. Riggins G.J., Kinzler K.W., Vogelstein B., Thiagalingam S. Frequency of Smad gene mutations in human cancers. Cancer Res. 57:1997;2578-2580.
228. Hayashi H., Abdollah S., Qiu Y., Cai J., Xu Y.-Y., Grinnell B.W., Richardson M.A., Topper J.N., Gimbrone M.A.J., Wrana J.L., Falb D. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell. 89:1997;1165-1173.
229. D'Amico D., Carbone D.P., Johnson B.E., Meltzer S.J., Minna J.D. Polymorphic sites within the MCC and APC loci reveal very frequent loss of heterozygosity in human small cell lung cancer. Cancer Res. 52:1992;1996-1999.
230. Ohata H., Emi M., Fujiwara Y., Higashino K., Nakagawa K., Futagami R., Tsuchiya E., Nakamura Y. Deletion mapping of the short arm of chromosome 8 in non-small cell lung carcinoma. Genes Chrom. Cancer. 7:1993;85-88.
231. Sato S., Nakamura Y., Tsuchiya E. Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res. 54:1994;5652-5655.
232. Shiseki M., Kohno T., Nishikawa R., Sameshima Y., Mizoguchi H., Yokota J. Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung carcinoma. Cancer Res. 54:1994;5643-5648.
233. Bepler G., Garcia-Blanco M.A. Three tumor-suppressor regions on chromosome 11p identified by high-resolution deletion mapping in human non-small-cell lung cancer. Proc. Natl. Acad. Sci. USA. 91:1994;5513-5517.
234. Iizuka M., Sugiyama Y., Shiraishi M., Jones C., Sekiya T. Allelic losses in human chromosome 11 in lung cancers. Genes Chrom. Cancer. 13:1995;40-46.
235. Otsuka T., Kohno T., Mori M., Noguchi M., Hirohashi S., Yokota J. Deletion mapping of chromosome 2 in human lung carcinoma. Genes Chrom. Cancer. 16:1996;113-119.
236. O'Briant K.C., Bepler G. Delineation of the centromeric and telomeric chromosome segment 11p15.5 lung cancer suppressor regions LOH11A and LOH11B. Genes Chrom. Cancer. 18:1997;111-114.
237. Sekido Y., Pass H.I., Bader S., Mew D.J., Christman M.F., Gazdar A.F., Minna J.D. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 55:1995;1227-1231.
238. Cooper C.A., Bubb V.J., Smithson N., Carter R.L., Gledhill S., Lamb D., Wyllie A.H., Carey F.A. Loss of heterozygosity at 5q21 in non-small cell lung cancer: a frequent event but without evidence of apc mutation. J. Pathol. 180:1996;33-37.
239. Kohno T., Morishita K., Takano H., Shapiro D.N., Yokota J. Homozygous deletion at chromosome 2q33 in human small-cell lung carcinoma identified by arbitrarily primed PCR genomic fingerprinting. Oncogene. 9:1994;103-108.
240. Wieland I., Böhm M., Bogatz S. Isolation of DNA sequences deleted in lung cancer by genomic difference cloning. Proc. Natl. Acad. Sci. USA. 89:1992;9705-9709.
241. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., Bigner S.H., Giovanella B.C., Ittmann M., Tycko B., Hibshoosh H., Wigler M.H., Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1997;1943-1947.
242. E. Forgacs, E.J. Biesterveld, Y. Sekido, K. Fong, S. Muneer, I.I. Wistuba, S. Milchgrub, R. Brezinschek, A. Virmani, A.F. Gazdar, J.D. Minna, Mutation analysis of the PTEN/MMAC1 gene in lung cancer, Oncogene, in press.
243. Sundaresan V., Ganly P., Hasleton P., Rudd R., Sinha G., Bleehen N.M., Rabbitts P. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene. 7:1992;1989-1997.
244. Nuorva K., Soini Y., Kamel D., Autio-Harmainen H., Risteli L., Risteli J., Vähäkangas K., Pääkkö P. Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am. J. Pathol. 142:1993;725-732.
245. Bennett W.P., Colby T.V., Travis W.D., Borkowski A., Jones R.T., Lane D.P., Metcalf R.A., Samet J.M., Takeshima Y., Gu J.R., Vähäkangas K.H., Soini Y., Pääkkö P., Welsh J.A., Harris C.C. p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res. 53:1993;4817-4822.
246. Hirano T., Franzén B., Kato H., Ebihara Y., Auer G. Genesis of squamous cell lung carcinoma. Sequential changes of proliferation, DNA ploidy, and p53 expression. Am. J. Pathol. 144:1994;296-302.
247. Smith A.L., Hung J., Walker L., Rogers T.E., Vuitch F., Lee E., Gazdar A.F. Extensive areas of aneuploidy are present in the respiratory epithelium of lung cancer patients. Br. J. Cancer. 73:1996;203-209.
248. Betticher D.C., Heighway J., Thatcher N., Hasleton P.S. Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients. Br. J. Cancer. 75:1997;1761-1768.
249. Satoh Y., Ishikawa Y., Nakagawa K., Hirano T., Tsuchiya E. A follow-up study of progression from dysplasia to squamous cell carcinoma with immunohistochemical examination of p53 protein overexpression in the bronchi of ex-chromate workers. Br. J. Cancer. 75:1997;678-683.
250. Li Z.H., Zheng J., Weiss L.M., Shibata D. c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am. J. Pathol. 144:1994;303-309.
251. Chung G.T.Y., Sundaresan V., Hasleton P., Rudd R., Taylor R., Rabbitts P.H. Sequential molecular genetic changes in lung cancer development. Oncogene. 11:1995;2591-2598.
252. Hung J., Kishimoto Y., Sugio K., Virmani A., McIntire D.D., Minna J.D., Gazdar A.F. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. J. Am. Med. Assoc. 273:1995;558-563.
253. Kishimoto Y., Sugio K., Hung J.Y., Virmani A.K., McIntire D.D., Minna J.D., Gazdar A.F. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J. Natl. Cancer Inst. 87:1995;1224-1229.
254. Sugio K., Kishimoto Y., Virmani A.K., Hung J.Y., Gazdar A.F. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res. 54:1994;5811-5815.
255. Westra W.H., Baas I.O., Hruban R.H., Askin F.B., Wilson K., Offerhaus G.J., Slebos R.J. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res. 56:1996;2224-2228.
256. Slaughter D.P., Southvick H.W., Smejkal W. 'Field cancerization' in oral stratified squamous epithelium - clinical implications of multicentric origin. Cancer. 6:1953;963-968.
257. Franklin W.A., Gazdar A.F., Haney J., Wistuba I.I., La Rosa F.G., Kennedy T., Ritchey D.M., Miller Y.E. Widely dispersed p53 mutation in respiratory epithelium: a novel mechanism for field carcinogenesis. J. Clin. Invest. 100:1997;2133-2137.
258. Peltomäki P., Lothe R.A., Aaltonen L.A., Pylkkänen L., Nyström-Lahti M., Seruca R., David L., Holm R., Ryberg D., Haugen A., Brøgger A., Børresen A.-L., de la Chapelle A. Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. Cancer Res. 53:1993;5853-5855.
259. Mao L., Lee D.J., Tockman M.S., Erozan Y.S., Askin F., Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer. Proc. Natl. Acad. Sci. USA. 91:1994;9871-9875.
260. Merlo A., Mabry M., Gabrielson E., Vollmer R., Baylin S.B., Sidransky D. Frequent microsatellite instability in primary small cell lung cancer. Cancer Res. 54:1994;2098-2101.
261. Shridhar V., Siegfried J., Hunt J., del Mar Alonso M., Smith D.I. Genetic instability of microsatellite sequences in many non-small cell lung carcinomas. Cancer Res. 54:1994;2084-2087.
262. Ryberg D., Lindstedt B.A., Zienolddiny S., Haugen A. A hereditary genetic marker closely associated with microsatellite instability in lung cancer. Cancer Res. 55:1995;3996-3999.
263. Fong K.M., Zimmerman P.V., Smith P.J. Microsatellite instability and other molecular abnormalities in non-small cell lung cancer. Cancer Res. 55:1995;28-30.
264. Adachi J., Shiseki M., Okazaki T., Ishimaru G., Noguchi M., Hirohashi S., Yokota J. Microsatellite instability in primary and metastatic lung carcinomas. Genes Chrom. Cancer. 14:1995;301-306.
265. Chen X.Q., Stroun M., Magnenat J.-L., Nicod L.P., Kurt A.-M., Lyautey J., Lederrey C., Anker P. Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat. Med. 2:1996;1033-1035.
266. Hurr K., Kemp B., Silver S.A., El-Naggar A.K. Microsatellite alteration at chromosome 3p loci in neuroendocrine and non-neuroendocrine lung tumors. Histogenetic and clinical relevance. Am. J. Pathol. 149:1996;613-620.
267. Rosell R., Pifarré A., Monzó M., Astudillo J., López-Cabrerizo M.P., Calvo R., Moreno I., Sánchez-Céspedes M., Font A., Navas-Palacios J.J. Reduced survival in patients with stage-I non-small-cell lung cancer associated with DNA-replication errors. Int. J. Cancer. 74:1997;330-334.
268. Sekine I., Yokose T., Ogura T., Suzuki K., Nagai K., Kodama T., Mukai K., Nishiwaki Y., Esumi H. Microsatellite instability in lung cancer patients 40 years of age or younger. Jpn. J. Cancer Res. 88:1997;559-563.
269. Miozzo M., Sozzi G., Musso K., Pilotti S., Incarbone M., Pastorino U., Pierotti M.A. Microsatellite alterations in bronchial and sputum specimens of lung cancer patients. Cancer Res. 56:1996;2285-2288.
270. Lindstedt B.-A., Ryberg D., Haugen A. Rare alleles at different VNTR loci among lung-cancer patients with microsatellite instability in tumours. Int. J. Cancer. 70:1997;412-415.
271. Hiyama K., Ishioka S., Shirotani Y., Inai K., Hiyama E., Murakami I., Isobe T., Inamizu T., Yamakido M. Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in p53 and Rb. Oncogene. 10:1995;937-944.
272. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:1994;2011-2015.
273. Hiyama K., Hiyama E., Ishioka S., Yamakido M., Inai K., Gazdar A.F., Piatyszek M.A., Shay J.W. Telomerase activity in small-cell and non-small-cell lung cancers. J. Natl. Cancer Inst. 87:1995;895-902.
274. Albanell J., Lonardo F., Rusch V., Engelhardt M., Langenfeld J., Han W., Klimstra D., Venkatraman E., Moore M.A.S., Dmitrovsky E. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J. Natl. Cancer Inst. 89:1997;1609-1615.
275. Yashima K., Litzky L.A., Kaiser L., Rogers T., Lam S., Wistuba I.I., Milchgrub S., Srivastava S., Piatyszek M.A., Shay J.W., Gazdar A.F. Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res. 57:1997;2373-2377.
276. Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., Caddle S.D., Ziaugra L., Beijersbergen R.L., Davidoff M.J., Liu Q., Bacchetti S., Haber D.A., Weinberg R.A. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 90:1997;785-795.
277. WAF1. Science. 277:1997;1996-2000.
278. Stirzaker C., Millar D.S., Paul C.L., Warnecke P.M., Harrison J., Vincent P.C., Frommer M., Clark S.J. Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Res. 57:1997;2229-2237.
279. Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., Samid D., Duan D.S., Gnarra J.R., Linehan W.M., Baylin S.B. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA. 91:1994;9700-9704.
280. Makos M., Nelkin B.D., Lerman M.I., Latif F., Zbar B., Baylin S.B. Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer. Proc. Natl. Acad. Sci. USA. 89:1992;1929-1933.
281. Suzuki H., Ueda R., Takahashi T., Takahashi T. Altered imprinting in lung cancer. Nat. Genet. 6:1994;332-333.
282. Kondo M., Suzuki H., Ueda R., Osada H., Takagi K., Takahashi T., Takahashi T. Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers. Oncogene. 10:1995;1193-1198.
283. Gazdar A.F., Minna J.D. Cigarettes, sex, and lung adenocarcinoma. J. Natl. Cancer Inst. 89:1997;1563-1565.
284. Thun M.J., Lally C.A., Flannery J.T., Calle E.E., Flanders W.D., Heath C.W.J. Cigarette smoking and changes in the histopathology of lung cancer. J. Natl. Cancer Inst. 89:1997;1580-1586.
285. Spitz M.R., Hsu T.C., Wu X., Fueger J.J., Amos C.I., Roth J.A. Mutagen sensitivity as a biological marker of lung cancer risk in African Americans. Cancer Epidemiol. Biomarkers Prev. 4:1995;99-103.
286. N. Caporaso, M.R. DeBaun, N. Rothman, Lung cancer and CYP2D6 (the debrisoquine polymorphism): sources of heterogeneity in the proposed association, Pharmacogenetics (1995) S129-134.
287. Christensen P.M., Gotzsche P.C., Brosen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur. J. Clin. Pharmcol. 51:1997;389-393.
288. Bouchardy C., Benhamou S., Dayer P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res. 56:1996;251-253.
289. London S.J., Daly A.K., Leathart J.B.S., Navidi W.C., Carpenter C.C., Idle J.R. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis. 18:1997;1203-1214.
290. Legrand M., Stücker I., Marez D., Sabbagh N., Lo-Guidice J.M., Broly F. Influence of a mutation reducing the catalytic activity of the cytochrome P450 CYP2D6 on lung cancer susceptibility. Carcinogenesis. 17:1996;2267-2269.
291. Cascorbi I., Brockmöller J., Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung
292. Kawajiri K., Eguchi H., Nakachi K., Sekiya T., Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res. 56:1996;72-76.
293. Goto I., Yoneda S., Yamamoto M., Kawajiri K. Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res. 56:1996;3725-3730.
294. Crofts F., Taioli E., Trachman J., Cosma G.N., Currie D., Toniolo P., Garte S.J. Functional significance of different human CYP1A1 genotypes. Carcinogenesis. 15:1994;2961-2963.
295. Persson I., Johansson I., Ingelman-Sundberg M. In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility. Biochem. Biophys. Res. Commun. 231:1997;227-230.
296. 462: assessment of a role for the rare allele in carcinogenesis. Cancer Res. 56:1996;3926-3933.
297. Ryberg D., Skaug V., Hewer A., Phillips D.H., Harries L.W., Wolf C.R., Øgreid D., Ulvik A., Vu P., Haugen A. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis. 18:1997;1285-1289.
298. Hirvonen A., Saarikoski S.T., Linnainmaa K., Koskinen K., Husgafvel-Pursiainen K., Mattson K., Vainio H. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders. J. Natl. Cancer Inst. 88:1996;1853-1856.
299. van Poppel G., de Vogel N., van Balderen P.J., Kok F.J. Increased cytogenetic damage in smokers deficient in glutathione S-transferase isozyme μ Carcinogenesis. 13:1992;303-305.
300. Kato S., Bowman E.D., Harrington A.M., Blomeke B., Shields P.G. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J. Natl. Cancer Inst. 87:1995;902-907.
301. Tokuhata G.K., Lilienfeld A.M. Familial aggregation of lung cancer among hospital patients. Public Health Rep. 78:1963;277-283.
302. Ooi W.L., Elston R.C., Chen V.W., Bailey-Wilson J.E., Rothschild H. Increased familial risk for lung cancer. J. Natl. Cancer Inst. 76:1986;217-222.
303. Schwartz A.G., Yang P., Swanson G.M. Familial risk of lung cancer among nonsmokers and their relatives. Am. J. Epidemiol. 144:1996;554-562.
304. Sellers T.A., Bailey-Wilson J.E., Elston R.C., Wilson A.F., Elston G.Z., Ooi W.L., Rothschild H. Evidence for mendelian inheritance in the pathogenesis of lung cancer. J. Natl. Cancer Inst. 82:1990;1272-1279.
305. Sellers T.A., Bailey-Wilson J.E., Potter J.D., Rich S.S., Rothschild H., Elston R.C. Effect of cohort differences in smoking prevalence on models of lung cancer susceptibility. Genet. Epidemiol. 9:1992;261-271.
306. Bailey-Wilson E., Elston R., Sellers T., Rotschild H. Segregation analysis of lung cancer using Class A regressive models. Am. J. Hum. Genet. 51:1992;A145.
307. Braun M.M., Caporaso N.E., Page W.F., Hoover R.N. Genetic component of lung cancer: cohort study of twins. Lancet. 344:1994;440-443.
308. Dragani T.A., Manenti G., Pierotti M.A. Genetics of murine lung tumors. Adv. Cancer Res. 67:1995;83-112.
309. Redondo M., Concha A., Oldiviela R., Cueto A., Gonzalez A., Garrido F., Ruiz-Cabello F. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters. Cancer Res. 51:1991;4948-4954.
310. Korkolopoulou P., Kaklamanis L., Pezzella F., Harris A.L., Gatter K.C. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br. J. Cancer. 73:1996;148-153.
311. Chen H.L., Gabrilovich D., Virmani A., Ratnani I., Girgis K.R., Nadaf-Rahrov S., Fernandez-Vina M., Carbone D.P. Structural and functional analysis of β2 microglobulin abnormalities in human lung and breast cancer. Int. J. Cancer. 67:1996;756-763.
312. Singal D.P., Ye M., Qiu X. Molecular basis for lack of expression of HLA class I antigens in human small-cell lung carcinoma cell lines. Int. J. Cancer. 68:1996;629-636.
313. Chen H.L., Gabrilovich D., Tampe R., Girgis K.R., Nadaf S., Carbone D.P. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat. Genet. 13:1996;210-213.
314. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J., Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1996;1363-1366.
315. Strand S., Hofmann W.J., Hug H., Muller M., Otto G., Strand D., Mariani S.M., Stremmel W., Krammer P.H., Galle P.R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nat. Med. 2:1996;1361-1366.
316. Niehans G.A., Brunner T., Frizelle S.P., Liston J.C., Salerno C.T., Knapp D.J., Green D.R., Kratzke R.A. Human lung carcinomas express Fas ligand. Cancer Res. 57:1997;1007-1012.
317. Mason R.J., Williams M.C., Moses H.L., Mohla S., Berberich M.A. Stem cells in lung development, disease, and therapy. Am. J. Respir. Cell Mol. Biol. 16:1997;355-363.
318. Williams C.L. Basic science of small cell lung cancer. Chest Surg. Clin. N. Am. 7:1997;1-19.
319. Vuitch F., Sekido Y., Fong K., Mackay B., Minna J.D., Gazdar A.F. Neuroendocrine tumors of the lung. Pathology and molecular biology. Chest Surg. Clin. N. Am. 7:1997;21-47.
320. Borges M., Linnoila R.I., van de Velde H.J., Chen H., Nelkin B.D., Mabry M., Baylin S.B., Ball D.W. An achaete-scute homologue essential for neuroendocrine differentiation in the lung. Nature. 386:1997;852-855.
321. Guillemot F., Lo L.C., Johnson J.E., Auerbach A., Anderson D.J., Joyner A.L. Mammalian achaete-scute homolog 1 is required for the early development of olfactory and autonomic neurons. Cell. 75:1993;463-476.
322. Penno M.B., August J.T., Baylin S.B., Mabry M., Linnoila R.I., Lee V.S., Croteau D., Yang X.L., Rosada C. Expression of CD44 in human lung tumors. Cancer Res. 54:1994;1381-1387.
323. Tran T.A., Kallakury B.V.S., Sheehan C.E., Ross J.S. Expression of CD44 standard form and variant isoforms in non-small cell lung carcinomas. Hum. Pathol. 28:1997;809-814.
324. Falco J.P., Baylin S.B., Lupu R., Borges M., Nelkin B.D., Jasti R.K., Davidson N.E., Mabry M. v-rasH induces non-small cell phenotype, with associated growth factors and receptors, in a small cell lung cancer cell line. J. Clin. Invest. 85:1990;1740-1745.